Drug analysis

Cabometyx

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple tyrosine kinases including MET, AXL, and vascular endothelial growth factor receptor (VEGFR).

capivasertib

Capivasertib (AstraZeneca) is an orally active, highly selective Akt inhibitor that preferentially targets Akt isoforms 1–3. Akt is a key enzyme in the PI3K/Akt/mTOR tumor cell survival pathway and is dysregulated in a number of malignancies through loss of tumor suppressor phosphatase and tensin homolog (PTEN), acquisition of activating mutations in phosphatidylinositol-4,5-bisphosphate 3- kinase catalytic subunit alpha (PIK3CA) or AKT1, as well as amplification of PI3K.

CB-839

Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.

Cenicriviroc

Cenicriviroc (Allergan/Takeda) is a potent immunomodulator that blocks the chemokine receptors-2/5 (CCR-2/5). CCR-2/5 have been linked to the inflammatory and fibrogenic pathways in non-alcoholic steatohepatitis (NASH), and by inhibiting CCR-2/5 it is anticipated that cenicriviroc will reduce inflammation and fibrosis.

ChimeriVax-Dengue

ChimeriVax-Dengue (Sanofi Pasteur) is a tetravalent vaccine comprised of four monovalent, chimeric LAVs.

Cinqair

Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma.

Cometriq

Cometriq is an orally available small molecule inhibitor currently being developed by Exelixis as

second-line therapy for patients with relapsed or metastatic RCC.

Copaxone

Copaxone is an immunomodulator composed of four amino acids found in myelin basic protein, believed to act by modifying immune processes in the pathogenesis of MS. It was the third disease-modifying MS drug to be available in the US, following its April 1997 launch.

Cosentyx

Cosentyx (secukinumab; Novartis) is a fully human monoclonal antibody which acts by neutralizing interleukin (IL)-17A. IL-17A is a pro-inflammatory cytokine secreted by activated T cells. It is indicated for the treatment of plaque psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis.

Crenezumab

Crenezumab, created by AC Immune’s SupraAntigen technology platform, is a fully humanized

immunoglobulin G4 monoclonal antibody (MAb) that recognizes amyloid-beta’s mid-section

(Alzforum, 2015).